SAN CLEMENTE, Calif. and NEW ORLEANS, Nov. 4, 2016 /PRNewswire/ -- BOOTH #501 -- ReShape Medical Inc. today announced results from the use of the ReShape Integrated Dual Balloon System since FDA approval, which demonstrate a significant increase in weight loss over the clinical trial experience.
Data obtained from the ReShape Patient Portal, an online support community where patients can interact with each other and track their progress, show benefits of the ReShape Dual Balloon as well as its associated coaching. The first 100 patients who received the ReShape Procedure in the commercial setting lost an average of 29.1 pounds, a 77% increase compared to patients in the clinical trial who lost an average of 16.4 pounds after six months. ReShape was also able to ascertain that patients who remained highly engaged on the Portal lost two times as much weight over a six-month period than patients with low engagement. "We are excited to see the life-changing, real world positive results from patients who have received the ReShape Dual Balloon," said Michael J. Mangano, President and Chief Executive Officer, ReShape Medical®. "With our first patients now 12 months out from balloon insertion, outcomes reinforce the dual balloon as an effective treatment option for patients who haven't succeeded with diet and exercise alone. We are routinely achieving 10% total body weight loss, which scientific evidence demonstrates improves obesity-related conditions such as high cholesterol, hypertension, and others." Two studies were also presented to leaders in bariatric surgery at the annual ObesityWeek national medical conference this week. Both studies showed impressive weight loss results with at least 33.2%, and up to 37.6%, excess weight loss (EWL) achieved for patients with three or more months of treatment, as compared to the clinical study results of 27.9% EWL.